Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort

Table 1

Demographic, clinical, and genetic results of anti-Jo-1 positive patients.

	Anti-Jo-1 positive patients		HLA-DRB103 positive patients		HLA-DRB103 negative patients		p value
Number of patients:	49		20		9		-
Male/Female:	7/42		1/19		2/7		0.22
Average age at disease onset ± SD (youngest-oldest):	43.4 ±13.28; (18-70)		40.4±13.9		40.22±14.55		0.703
Median follow-up time ± SD (years)	10.1 ±6.51		11.5±6.79		12.33±5.34		0.748
Average CK at diagnosis (U/l) ± SD	3003.25 ±3101.8		2816.30 ±2417.36		5969.44 ±3842.89		0.045
Average LDH at diagnosis (U/l) ± SD	922.33 ±635.32		891.78±661.3		1292.57 ±737.948		0.2
Average CRP at diagnosis (mg/l) ± SD	22.49 ±22.09		18.32±22.55		23.99±17.17		0.542
Average ESR at diagnosis (mm/h) ± SD	24.24 ±15.96		21.50±13.57		24.89±14.46		0.547
myositis:	49/49	100%	20/20	100%	9/9	100%	1.0
ILD/alveolitis:	35/48	73%	15/20	75%	7/9	78%	1.0
arthritis/arthralgia:	43/49	88%	16/20	80%	8/9	89%	1.0
dysphagia:	6/49	12%	3/20	15%	1/9	11%	1.0
fever:	21/49	43%	7/20	35%	6/9	67%	0.226
Raynaud’s phenomenon:	32/49	65%	10/20	50%	8/9	89%	0.096
mechanic’s hand:	16/49	33%	5/20	25%	5/9	56%	0.205
subcutaneous calcinosis:	3/49	6%	1/20	5%	1/9	11%	0.532
SSA positivity:	17/49	35%	7/20	35%	2/9	22%	0.675
mortality:	5/49	10%	3/20	15%	0/9	0%	0.532
Maintenance dose of steroid (mg):	5.57±8.44		3.90±3.81		3.44±3.644		0.765